Assessing liver fibrosis without biopsy in patients with HCV or NAFLD

ABSTRACT

Staging of liver fibrosis is increasingly done using noninvasive methods, in some cases obviating the need for liver biopsy. Scores based on laboratory values and demographic variables have been developed and validated for assessing fibrosis in patients with hepatitis C virus (HCV) infection and nonalcoholic fatty liver disease (NAFLD), as have several imaging methods that measure shear-wave velocity, a reflection of fibrosis severity.

KEY POINTS

Liver biopsy remains the gold standard for determining fibrosis stage but is expensive and entails risk of complications.

For patients infected with HCV, fibrosis stage should be determined with transient elastography, a transthoracic ultrasonographic technique that measures shear-wave velocity.

For patients with cirrhosis, transient elastography combined with a platelet count can detect developing portal hypertension and determine whether to screen for esophageal varices.

For NAFLD, combined elastography and NAFLD fibrosis score—which incorporates patient characteristics and laboratory test results—should be used to determine the need for liver biopsy.
**ASSESSING LIVER FIBROSIS**

**FIBROSIS: A KEY INDICATOR OF DISEASE SEVERITY**

With any form of liver disease, collagen is deposited in hepatic lobules over time, a process called fibrosis. Both HCV infection and NASH involve necroinflammation in the liver, hepatocyte apoptosis, and activation of stellate cells, leading to progressive collagen deposition in hepatic lobules. Fibrosis typically starts in the region of the central vein and portal tracts and eventually extends to other areas of the lobule.

Determining fibrosis severity is critical when a patient is diagnosed with chronic liver disease, as it predicts long-term clinical outcomes and death in HCV\(^8\) and NAFLD.\(^9\) Different staging systems have been developed to reflect the degree of fibrosis, based on its distribution as seen on liver biopsy (Table 1, Figure 1).

In HCV infection, advanced fibrosis is defined as stage 4 to 6 using the Ishak system\(^10\) or stage 3 to 4 using the Meta-analysis of Histological Data in Viral Hepatitis (META-VIR) system.\(^11\)

In NAFLD, advanced fibrosis is defined as stage 3 to 4 using the NASH Clinical Research Network system.\(^12\)

Staging fibrosis is also important so that patients with cirrhosis can be identified early to begin screening for hepatocellular carcinoma and esophageal varices to reduce the risks of illness and death. In addition, insurance companies often require documentation of fibrosis stage before treating HCV with the new direct-acting antiviral agents.

**LIVER BIOPSY IS STILL THE GOLD STANDARD**

Although invasive, liver biopsy remains the gold standard for determining fibrosis stage. Liver biopsies were performed “blindly” (without imaging) until the 1990s, but imaging-guided biopsy using ultrasonography was then developed, which entailed less pain and lower complication and hospitalization rates. Slightly more hepatic tissue is obtained with guided liver biopsy, but the difference was deemed clinically insignificant.\(^13\) Concern initially

---

**TABLE 1**

**Fibrosis staging systems for HCV and NAFLD**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Ishak staging for HCV(^10)</th>
<th>META-VIR staging for HCV(^11)</th>
<th>NASH Clinical Research Network staging system for NAFLD(^12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No fibrosis</td>
<td>No fibrosis</td>
<td>No fibrosis</td>
</tr>
<tr>
<td>1</td>
<td>Expansion of some portal areas with or without septa</td>
<td>Portal fibrosis without septa</td>
<td>Perisinusoidal or periportal fibrosis</td>
</tr>
<tr>
<td>2</td>
<td>Expansion of most portal areas with or without septa</td>
<td>Portal fibrosis with rare septa</td>
<td>Perisinusoidal and portal/periportal fibrosis</td>
</tr>
<tr>
<td>3</td>
<td>Expansion of most portal areas with occasional portal-portal bridging</td>
<td>Portal fibrosis with numerous septa</td>
<td>Bridging fibrosis</td>
</tr>
<tr>
<td>4</td>
<td>Expansion of portal areas with marked bridging (portal-portal, portal-central)</td>
<td>Cirrhosis</td>
<td>Cirrhosis</td>
</tr>
<tr>
<td>5</td>
<td>Marked bridging with occasional nodules (incomplete cirrhosis)</td>
<td>Cirrhosis</td>
<td>Cirrhosis</td>
</tr>
<tr>
<td>6</td>
<td>Cirrhosis</td>
<td>Cirrhosis</td>
<td>Cirrhosis</td>
</tr>
</tbody>
</table>

HCV = hepatitis C virus; META-VIR = Meta-analysis of Histological Data in Viral Hepatitis; NAFLD = nonalcoholic fatty liver disease; NASH = nonalcoholic steatohepatitis

---

**Fibrosis: a process of collagen deposition in hepatic lobules**

---
SINGH AND COLLEAGUES

Bleeding is the most worrisome complication of liver biopsy

Expansion of portal tract by fibrosis (trichrome stain, × 100)

In the setting of steatohepatitis, fibrosis starts in the centrilobular perisinusoidal region (trichrome stain, × 100)

A subset of nonalcoholic steatohepatitis cases reveals only portal-based fibrosis, consistent with stage 1C (left); the centrilobular region seen on the right is intact (trichrome stain, × 100)

Periportal fibrosis is characterized by expansion of portal tracts with irregular border and focal entrapment of hepatocytes (trichrome stain, × 200)

Bridges of fibrous tissue connecting two portal tracts in a hepatitis C case, supporting stage 3 (bridging fibrosis) (trichrome stain, × 100)

End-stage liver disease with multiple cirrhotic nodules, surrounded by fibrous bands (trichrome stain, × 100)

Figure 1. Findings on liver biopsy in nonalcoholic fatty liver disease and hepatitis C virus infection.
arose about the added cost involved with imaging, but imaging-guided biopsy was actually found to be more cost-effective.¹⁴

In the 2000s, transjugular liver biopsy via the right internal jugular vein became available. This method was originally used primarily in patients with ascites or significant coagulopathy. At first, there were concerns about the adequacy of specimens obtained to make an accurate diagnosis or establish fibrosis stage, but this limitation was overcome with improved techniques.¹⁵,¹⁶ Transjugular liver biopsy has the additional advantage of enabling one to measure the hepatic venous pressure gradient, which also has prognostic significance; a gradient greater than 10 mm Hg is associated with worse prognosis.¹⁷

Disadvantages of biopsy:
Complications, sampling errors
Liver biopsy has disadvantages. Reported rates of complications necessitating hospitalization using the blind method were as high as 6% in the 1970s,¹⁸ dropping to 3.2% in a 1993 study.¹⁹ Bleeding remains the most worrisome complication. With the transjugular method, major and minor complication rates are less than 1% and 7%, respectively.¹⁵,¹⁶ Complication rates with imaging-guided biopsy are also low.

Liver biopsy is also prone to sampling error. The number of portal tracts obtained in the biopsy correlates with the accuracy of fibrosis staging, and smaller samples may lead to underestimating fibrosis stage. In patients with HCV, samples more than 15 mm long led to accurate staging diagnosis in 65% of patients, and those longer than 25 mm conferred 75% accuracy.²⁰ Also, different stages can be diagnosed from samples obtained from separate locations in the liver, although rarely is the difference more than a single stage.²¹

Histologic evaluation of liver biopsies is operator-dependent. Although significant interobserver variation has been reported for degree of inflammation, there tends to be good concordance for fibrosis staging.²²,²³

STAGING BASED ON DEMOGRAPHIC AND LABORATORY VARIABLES
Several scores based on patient characteristics and laboratory values have been developed for assessing liver fibrosis and have been specifi-
ry care physicians, the NAFLD fibrosis score is more cost-effective than transient elastography and liver biopsy for accurately predicting advanced fibrosis.30

**AST-to-platelet ratio index score for HCV, NAFLD**

The AST-to-platelet ratio index (APRI) score was developed in 2003 using a cohort of 270 patients with HCV and liver biopsy as the standard. A cutoff value of less than or equal to 0.5 had a negative predictive value of 86% for the absence of significant fibrosis, while a score of more than 1.5 detected the presence of significant fibrosis with a positive predictive value of 88%.31 The APRI score was subsequently validated for NAFLD.27,32

**FibroSure uses a patented formula**

FibroSure (LabCorp; labcorp.com) uses a patented mathematical formula that takes into account age, sex, and levels of gamma-glutamyl transferase, total bilirubin, haptoglobin, apolipoprotein-A, and alpha-2 macroglobulin to assess fibrosis. Developed in 2001 for use in patients with HCV infection, it was reported to have a positive predictive value of greater than 90% and a negative predictive value of 100% for clinically significant fibrosis, defined as stage 2 to 4 based on the META VIR staging system in the prediction model.33 The use of FibroSure in patients with HCV was subsequently validated in various meta-analyses and systematic reviews.34,35 It is less accurate in patients with normal ALT levels.36

FibroSure also has good accuracy for predicting fibrosis stage in chronic liver disease due to other causes, including NAFLD.37

The prediction models discussed above use routine laboratory tests for chronic liver disease and thus are inexpensive. The high cost of additional testing needed for FibroSure, coupled with the risk of misdiagnosis, makes its cost-effectiveness questionable.38

### IMAGING TO PREDICT FIBROSIS STAGE

Conventional ultrasonography (with or without vascular imaging) and computed tomography can detect cirrhosis on the basis of certain imaging characteristics,39,40 including the nodular contour of the liver, caudate lobe hypertrophy, ascites, reversal of blood flow in the portal vein, and splenomegaly. However, they cannot detect fibrosis in its early stages.

The 3 methods discussed below provide more accurate fibrosis staging by measuring the velocity of shear waves sent across hepatic tissue. Because shear-wave velocity increases with liver stiffness, the fibrosis stage can be estimated from this information.41

**Transient elastography**

Transient elastography uses a special ultrasound transducer. It is highly accurate for predicting advanced fibrosis for almost all causes of chronic liver disease, including HCV infection42,43 and NAFLD.44 The cutoff values of wave velocity to estimate fibrosis stage differ by liver disease etiology.

Transient elastography should not be used to evaluate fibrosis in patients with acute hepatitis, which transiently increases liver stiffness, resulting in a falsely high fibrosis stage diagnosis.45 It is also not a good method for evaluating fibrosis in patients with biliary obstruction or extrahepatic venous congestion. Because liver stiffness can increase after eating,46 the test should be done under fasting conditions.

A significant limitation of transient elastography has been its poor accuracy in patients with obesity.47 This has been largely overcome with the use of a more powerful (XL) probe but is still a limitation for those with morbid obesity.48 Because many patients with NAFLD are obese, this limitation can be significant.

Transient elastography has gained popularity for evaluating fibrosis in patients with chronic liver disease for multiple reasons: it is cost-effective and results are highly reproducible, with low variation in results among different observers and in individual observers.49 Combined with a platelet count, it can also be used to detect the development of clinically significant portal hypertension in patients with cirrhosis, thus determining the need to screen for esophageal varices using endoscopy.50 Screening endoscopy can be avoided in patients whose liver stiffness remains below 20 kPa or whose platelet count is above \(150 \times 10^9/L\).

**Acoustic radiation force imaging**

Unlike transient elastography, which requires a separate transducer probe to assess shear-wave velocity, acoustic radiation force imaging uses the same transducer for both this
function and imaging. Different image modes are available when testing for liver stiffness, so a region of interest that is optimal for avoiding vascular structures or masses can be selected, increasing accuracy.51

Acoustic radiation force imaging has been tested in different causes of chronic liver disease, including HCV and NAFLD,52 with accuracy similar to that of transient elastography.53 For overweight and obese patients, acoustic radiation force imaging is more accurate than transient elastography using the XL probe.54 However, this method is still new, and we need more data to support using one method over the other.

Magnetic resonance elastography
Magnetic resonance elastography uses a special transducer placed under the rib cage to transmit shear waves concurrently with magnetic resonance imaging. It has been tested in patients with HCV and NAFLD and has been found to have better diagnostic accuracy than transient elastography and acoustic radiation force imaging.55,56 Patients must be fasting for better diagnostic accuracy57 and must hold their breath while elastography is performed. The need for breath-holding and the high cost limit the use of this method for assessing fibrosis.

■ BOTTOM LINE FOR ASSESSING FIBROSIS

Although liver biopsy remains the gold standard for accurately determining fibrosis stage, noninvasive methods, especially imaging techniques, are fast evolving. Guidelines recommend using transient elastography to determine fibrosis stage noninvasively in patients with HCV,58 but a similar recommendation cannot be made for NAFLD with available data. For NAFLD, combined elastography and NAFLD fibrosis score are recommended to determine the need for a liver biopsy (Figure 2).59 Currently, we recommend using a combination of the scores discussed above and the imaging tests.

■ REFERENCES

doi:10.1002/hep.510240201


32. Vong VW, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59(9):1265–1269. doi:10.1136/gut.2010.216077


ADDRESS: Arthur J. McCullough, MD, Department of Gastroenterology and Hepatology, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; mcculla@ccf.org